NCT04020185 - Safety and Efficacy Study of IMSA101 in Refractory Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 23, 2019

Primary Completion Date

September 15, 2023

Study Completion Date

September 15, 2023

Conditions

Solid Tumor, Adult

Interventions

DRUG

IMSA101

IMSA101 administered by intra-tumoral (IT) injection on Day 1 of Weeks 1, 2, and 3 for Cycle 1 and on Day 1 of Weeks 1 and 3 for all subsequent cycles.

DRUG

Immune checkpoint inhibitor (ICI)

Administered according to product label

DRUG

Immuno-oncology (IO) therapy

Administered according to product label

Trial Locations (6)

60611

Northwestern University, Chicago

75390

UT Southwestern, Dallas

77030

MD Anderson Cancer Center, Houston

85260

Honor Health, Scottsdale

92093

UC San Diego Moores Cancer Center, La Jolla

07962

Atlantic Health System/Morristown Medical Center, Morristown